📰 Kaplan Meier News
Page 8 - Kaplan Meier News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kaplan Meier. Real-time updates on events, politics, business and more.
January 6, 2022
Section 1135 emergency waivers were designed as tools for policy-makers to rapidly increase health system capacity during a disaster. Granting regulatory, administrative, or payment-model flexibilities during the covid-19 pandemic, states may be better...
October 6, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
October 6, 2021
/PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent)...
October 6, 2021
/PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent)...
October 5, 2021
/PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial...
October 5, 2021
A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.
June 25, 2021
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ -- Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor Libtayo now approved by the European Commission for three advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo ® (cemiplimab) to treat adults with locally advanced or meta...
June 25, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
June 25, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation. Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma June 25, 2021 GMT TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ -- Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor Libtayo now approved by the Europe...
June 25, 2021
Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma Approval based on data